Archives
-
Q-VD-OPh: What the Evidence Really Shows
2026-10-13
Q-VD-OPh is widely described as an irreversible pan-caspase inhibitor, but its value in apoptosis research depends on how broadly caspase activity is interpreted and how well pharmacological effects are separated from other cell-death pathways. A 2022 Cell Reports study used caspase inhibition within a model of post-near-death tumor-cell states, linking survival from impending cell death with prometastatic behavior. The findings are mechanistically important but remain bounded by model choice, pharmacological specificity and the absence of clinical evidence.
-
RHEB Neddylation: Evidence and Open Gaps
2026-10-13
A source-grounded assessment of the reported UBE2F–SAG–RHEB–mTORC1 relationship, emphasizing what the 2025 study establishes, what remains correlative, and why the X-press Tag Peptide product description should not be treated as evidence for the cancer mechanism.
-
Cisapride and Deep-Learning Cardiotoxicity Screens
2026-10-12
The reported study supports iPSC-derived cardiomyocytes combined with high-content imaging and deep learning as an exploratory approach to detect cellular patterns associated with cardiotoxicity. It does not, from the supplied evidence, establish that Cisapride or R 51619 was included in the screened library, nor does it replace mechanistic, electrophysiological, translational, or clinical evaluation.
-
HIV-1 Nuclear Pore Remodeling in Resting T Cells
2026-10-10
Mesner et al. identify nuclear import at the nuclear pore complex as a major barrier to HIV-1 infection of resting CD4+ T cells and show how cell–cell spread overcomes it. The study links virological-synapse contact to CD4–LCK signalling, CDK1 activation, nucleoporin phosphorylation and enhanced viral nuclear import, offering a mechanistic explanation for infection of resting T cells in vivo.
-
RSL3 and GPX4 Inhibition in Ferroptosis Research
2026-10-09
RSL3 is a widely used glutathione peroxidase 4 inhibitor for investigating ferroptosis, redox vulnerability, and cancer-cell dependence on lipid peroxide control. This overview compares mechanistic evidence, oncogenic RAS associations, preclinical tumor findings, and important limitations, including compound-specific confounding and the absence of clinical validation.
-
Cisplatin and Ferroptosis: Five Key Questions
2026-10-09
A source-grounded overview of Cisplatin and CDDP research, explaining DNA damage principles, the evidence for Buzhong Yiqi Decoction in a cisplatin-resistant lung cancer cell model, and the study’s limitations and applicability boundaries.
-
ATF5 Peptide Downregulates CYP2B6 in Glioblastoma
2026-10-08
A 2025 study identifies ATF5 as a regulator of CYP2B6 in glioblastoma cells and shows that a TAT-fused dominant-negative ATF5 peptide lowers CYP2B6 protein in LN229 and GBM5 models. The findings connect transcription-factor biology with pharmacogenomics, while remaining preliminary because the study did not establish altered drug metabolism, clinical dosing effects, or in vivo efficacy.
-
Psoralen and Isopsoralen Activate ERK1/2 in Cholestasis
2026-10-08
A 2024 Chemical Research in Toxicology study used zebrafish larvae to connect the estrogen-like activity of psoralen and isopsoralen with cholestatic liver injury, altered bile-acid regulation, and increased ERK1/2 phosphorylation. Pharmacological rescue supports ERK1/2 as a mechanistically relevant node, while the model remains insufficient to establish human clinical risk or therapeutic efficacy.
-
Z-YVAD-FMK in Ferroptosis and Caspase-1 Research
2026-10-07
Z-YVAD-FMK is commonly presented as a caspase-1 inhibitor for studying inflammasome signaling and pyroptosis. Its relevance to ferroptosis research is indirect: the supplied AML study identifies dihomo-γ-linolenic acid and ACSL4-mediated lipid remodeling as drivers of ferroptotic leukemia-cell death, but it does not establish a role for caspase-1 or report use of Z-YVAD-FMK. This overview compares the pathways, explains what the published findings support, and defines the evidence and applicability limits without treating supplier claims as independent validation.
-
Z-YVAD-FMK in Caspase-1 and Pyroptosis Research
2026-10-07
A source-grounded overview of Z-YVAD-FMK as a research tool for studying caspase-1, pyroptosis, and inflammatory cell death, with emphasis on the HOXC8–CASP1 axis in non-small cell lung cancer and the limits of translating YVAD-based pharmacology to this specific compound.
-
Enzymatic Fatty Amine Synthesis from Trilaurin
2026-10-06
The reference study presents a one-pot enzyme cascade that converts renewable triglycerides and oils directly into medium- and long-chain primary fatty amines. Using Trilaurin as a representative substrate, the authors report analytical yields up to 97% and a 73% isolated yield for laurylamine, while also defining the proof-of-concept limits of the approach.
-
Cycloheximide in Protein Turnover Research
2026-10-06
Cycloheximide is a translational elongation inhibitor used conceptually to study protein synthesis, protein turnover, apoptosis, and cellular stress. This overview distinguishes supplier-reported properties from findings in a peer-reviewed triple-negative breast cancer study, explaining how translation suppression may help frame questions about protein stability without treating it as direct evidence for a therapeutic mechanism. It also compares evidence strength, highlights cytotoxicity and model-specific limitations, and defines boundaries for interpreting findings across cell, animal, and clinical contexts.
-
α-Amanitin: Mechanism, Research Uses, and Evidence
2026-10-05
A source-grounded overview of α-amanitin as an RNA polymerase II research probe, its conceptual applications in transcription and development studies, and emerging evidence linking STT3B and N-glycan biosynthesis to amatoxin toxicity.
-
Mutant Enzymes Reshape Pea Starch Digestion
2026-10-05
A 2026 study reports that engineered variants of a Bifidobacterium longum branching enzyme altered pea-starch architecture, reduced retrogradation, and increased the slowly digestible fraction in starch and cake models. The strongest effects were associated with S321D and E395D, although the evidence remains primarily biochemical, structural, and in vitro rather than clinical.
-
KX2-391 Dihydrochloride: Evidence and Context
2026-10-04
A source-grounded overview of KX2-391 dihydrochloride, also called Tirbanibulin dihydrochloride, covering its proposed Src and tubulin mechanisms, reported oncology, HBV, BoNT/A and actinic keratosis relevance, and the limits of the available evidence.